Form 4: Stoke Therapeutics Exec Sells Shares Under 10b5-1 Plan

Stoke Therapeutics Chief Medical Officer Barry Ticho sold a total of 7,228 shares of common stock in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc., reported the sale of 7,228 shares of common stock.
• The transactions occurred on July 1, 2026, and were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
• A total of 6,728 shares were sold at a weighted average price of $32.615, with individual sale prices ranging from $32.18 to $33.05.
• An additional 500 shares were sold at a weighted average price of $33.2678, with individual sale prices ranging from $33.23 to $33.37.
• Following these transactions, Ticho beneficially owns 27,598 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the sale of shares by a key executive, despite being conducted under a pre-arranged plan.

Negatives

• Company executive sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sales were conducted under a Rule 10b5-1 plan, which is designed to mitigate insider trading concerns, but the act of selling by a key executive can still impact market perception.
• No specific reasons for the sale were provided beyond the execution of the trading plan.

Future Outlook

No forward-looking statements or guidance were provided in this filing, as it solely reports on past transactions.

Management Comments

• The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive.
• The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives in the biotechnology sector as they diversify holdings or manage personal finances. However, the volume and timing relative to company news can influence investor sentiment.

Stakeholder Impact

• Shareholders may view the executive's sale of stock as a potential negative signal, although the Rule 10b5-1 plan mitigates concerns about insider trading.
• Employees may be influenced by the executive's stock sales, potentially impacting morale if perceived as a lack of confidence in the company's future.

Key Dates

Recommendation

The filing reports routine insider selling under a Rule 10b5-1 plan, which is a standard practice and does not provide new information about the company's fundamental performance or future prospects. Therefore, a 'hold' recommendation is appropriate, pending further material developments.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Rule 10b5-1, Share Sale, Barry Ticho, Chief Medical Officer, Beneficial Ownership